Clinical Trial Detail

NCT ID NCT03516981
Title A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

MK-4280 + Pembrolizumab

Lenvatinib + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST